On Nov 30, 2018, Dr. Xiaoyan Chu, Senior Principal Scientist at Merck shared her latest research findings on how endogenous biomarkers are being investigated as probes for drug-transporter interactions. Her presentation provided an overview of recently identified biomarkers for studying the inhibition of liver and kidney transporters including the current strategies, utility, limitations and future directions.  This event was jointly sponsored by the Toxicology and Pharmaceutics Graduate Programs.